Director-affiliated fund sells $133.5M in Apogee Therapeutics stock
APGE has more than doubled off its 52-week low of $26.2.
Summary
A fund associated with Apogee Therapeutics directors sold $133.5 million worth of common stock, significantly reducing its direct holdings.
Key Events · Ownership and Investor Activity · APGE
-
Significant Insider-Affiliated Sale
Fairmount Healthcare Fund II L.P., an institutional investor with directors Peter Harwin and Tomas Kiselak on the board, sold 1,750,000 shares of common stock.
-
Substantial Transaction Value
The open market sale was valued at $133,525,000, indicating a material disposition of shares.
-
Major Reduction in Direct Holdings
The transaction reduced the fund's direct common stock holdings by approximately 85%, leaving 298,647 shares.
Analysis · APGE · Life Sciences
Fairmount Healthcare Fund II L.P., an institutional investor associated with directors Peter Harwin and Tomas Kiselak, executed a substantial open market sale of Apogee Therapeutics common stock. This transaction, valued at $133.5 million, represents a significant reduction in the fund's direct common stock holdings, decreasing them by approximately 85%. While the fund still holds a large amount of convertible non-voting common stock, this large-scale disposition of voting shares by an entity closely tied to the board could be interpreted as a loss of conviction or a strategic portfolio adjustment, potentially signaling a negative outlook to the market.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APGE was trading at $79.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $26.20 to $84.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.